Patoloxía Molecular das Doenzas Raras
PatMol-DR
![Foto de Patoloxía Molecular das Doenzas Raras](/img/grupo.png)
![Foto de Hospital de la Santa Creu i Sant Pau](/img/noimage_org.png)
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (43)
2024
-
Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA)
European Journal of Heart Failure
2023
-
Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care
Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269
-
Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial
International Journal of Cardiology, Vol. 391
-
Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction
Journal of Clinical Medicine, Vol. 12, Núm. 8
-
The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events
Journal of Clinical Lipidology, Vol. 17, Núm. 5, pp. 602-611
2022
-
Differences Between Takotsubo and the Working Diagnosis of Myocardial Infarction With Nonobstructive Coronary Arteries
Frontiers in Cardiovascular Medicine, Vol. 9
-
Renal Function Impact in the Prognostic Value of Galectin-3 in Acute Heart Failure
Frontiers in Cardiovascular Medicine, Vol. 9
-
Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial
BMC Cardiovascular Disorders, Vol. 22, Núm. 1
2021
-
A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure
Frontiers in Physiology, Vol. 12
-
Ischemic etiology and prognosis in men and women with acute heart failure
Journal of Clinical Medicine, Vol. 10, Núm. 8
-
Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice
REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48
-
Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival
Journal of the American Heart Association, Vol. 10, Núm. 2, pp. 1-21
-
Prognostic impact of hyponatraemia and hypernatraemia at admission and discharge in heart failure patients with preserved, mid-range and reduced ejection fraction
Internal Medicine Journal, Vol. 51, Núm. 6, pp. 930-938
-
Sex-related differences of fatty acid-binding protein 4 and leptin levels in atrial fibrillation
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 23, Núm. 5, pp. 682-690
2020
-
Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure
REC: CardioClinics, Vol. 55, Núm. 3, pp. 155-164
2019
-
Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction
Internal Medicine Journal, Vol. 49, Núm. 12, pp. 1505-1513
-
Patient-Associated Predictors of 15- and 30-Day Readmission After Hospitalization for Acute Heart Failure
Current Heart Failure Reports, Vol. 16, Núm. 6, pp. 304-314
2018
-
Myocardium of patients with dilated cardiomyopathy presents altered expression of genes involved in thyroid hormone biosynthesis
PLoS ONE, Vol. 13, Núm. 1
-
Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: A multicenter, double-blind, randomized clinical trial
European Heart Journal, Vol. 39, Núm. 15, pp. 1255-1264